Introduction

COST-EFFECTIVENESS ANALYSIS OF SIMVASTATIN ATORVASTATIN AND ATORVASTATIN-EZETIMIBE COMBINATION AMONG PATIENTS WITH DIABETES MELLITUS OR CARDIOVASCULAR DISEASE IN GENERAL PRACTICE
Lipid lowering drugs are benefit to reduced morbidity and mortality for CHD especially Statins. [1, 2] Cholesterol Treatment Trialists Collaborators were explain for relationship between LDL-C reduction and major coronary event or major vascular event. [3] NCEP ATP III guideline recommend treatment for the reduction of risk CHD from LDL-C reduction that is the primary outcome. [4, 5] Some high-risk CHD patients have poor outcomes with Statin therapy and need to use combination regimens. [6] Statin-Ezetimibe combination have an interesting option when compare double-dose of Statins or high potency Statins. [7, 8] The combination regimens are more LDL-C reduction than other regimens with high cost. The cost-effectiveness studies of combination regimens have not been widely found.
This study is aimed to analyze the cost-effectiveness of using Simvastatin, Atorvastatin, and AtorvastatinEzetimibe combination (A/E combination) among highrisk CHD outpatients in general practice on the provider perspective. Figure 1 showed that Three treatments had difference of direct medical cost. Simvastatin was less costly than Atorvastatin and A/E combination because Simvastatin is generic drug but other regimens are original. Our study found that main cost of the direct medical cost was a part of drug cost. Target of treatment according to NCEP ATP III had impact to differences of direct medical cost. Because aggressive goal was use intensive treatment for very high risk CHD patients who had high cost of treatment. Figure 2 showed that Simvastatin had the lowest intermediate outcomes compared to other regimens. A/E combination had the best LDL-C reduction because combination with two drugs of two mechanism are enhance the effectiveness. [9] In term standard goal, A/E combination had lower effectiveness than Atorvastatin because LDL-C before treatment that higher than Atorvastatin. The level of LDL-C before treatment was important to the proportion of achieving this target.
Objective
Methods and Data anlysis
Results and Discussion
Cost-effectiveness analysis (CEA)
[10] Table 1 represents the cost-effectiveness analysis. Atorvastatin was the best cost effectiveness for standard treatment. In case of aggressive goal showed that A/E combination provided the most cost-effectiveness. The recent study showed that high dose of Atorvastatin (80 mg/day) had costeffectiveness among familial hypercholesterolemia in Spain. Moreover, coadministration of Ezetimibe was increase effectiveness with acceptable cost (threshold 16,000 EUR per life year gained). [11] The cost-utility analysis showed that Atorvastatin was the cost-effectiveness in diabetes mellitus for primary prevention of CHD. In addition, it was useful in stroke patients for secondary prevention of CHD. Although the study was compare with placebo. [12, 13] 
Conclusion
Comparison treatment with Simvastatin, Atorvastatin and AtorvastatinEzetimibe combination among high-risk CHD outpatients who failed to achieve the treatment goal or had adverse drug reaction. showed that  Atorvastatin was more effectiveness and less costly than AtorvastatinEzetimibe combination in term of standard treatment.  Atorvastatin-Ezetimibe combination was an interesting option when aggressive treatment goal was used. This study provide the cost-effectiveness knowledge for developing the clinical practice guideline at the Chandrubeksa hospital in the near future. • 
